Top

BMC Cancer

Published in:

Open Access 01-12-2017 | Research article

Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival

Authors: Gang Li, Jianpeng Yu, Hualin Song, Shimiao Zhu, Libin Sun, Zhiqun Shang, Yuanjie Niu

Published in: BMC Cancer | Issue 1/2017

Abstract

Background

The independent prognostic role of squamous differentiation in pT1 bladder urothelial carcinoma has not been reported in previous studies. This article describes the impact of squamous differentiation on tumor recurrence and survival, and whether this histologic variant could indeed alter definitive treatment, based on single center-based retrospective data.

Methods

Totally, we retrieved (1)1449 histologically confirmed pT1 bladder urothelial carcinoma patients without histologic variants; (2)227 pT1 bladder urothelial carcinoma patients with squamous differentiation in our institution, from May 2004 to Oct 2015. The total amount of high/low grade urothelial carcinoma patients was 991/685 respectively. Transurethral resection of bladder tumor (TURBT) and intravesical chemotherapy were performed as initial treatments for all the patients. The clinical and pathological characteristics, treatment and survival outcomes were compared between squamous differentiation-positive and squamous differentiation-negative patients.

Results

In our study, 14% urothelial carcinoma patients were detected with squamous differentiation. The mean age of all the patients examined was 66.4, of whom 82% were males. The 5-year cancer specific survival rates were 69% for squamous differentiation-positive patients and 91% for squamous differentiation-negative patients (p < 0.001). Recurrence proved to be more common in squamous differentiation-positive patients than in negative patients. In the results of the univariate and multivariate Cox proportional hazard analysis, tumor size, lymphovascular invasion, recurrence and squamous differentiation were confirmed to be the prognostic factors associated with patients’ survival.

Conclusions

Squamous differentiation in pT1 bladder urothelial carcinoma is correlated to high risk of recurrence and poor prognosis as an independent prognostic factor. Radical cystectomy is essential for recurred high grade pT1 bladder urothelial carcinoma with squamous differentiation accompanied by lymphovascular invasion.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.21332.CrossRefPubMed

Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell’Oglio P, et al. Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: a 20-year single center experience. European J Surg Oncol: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2016;42(5):735–43. doi:10.1016/j.ejso.2016.02.011.CrossRef

Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2006;12(22):6663–76. doi:10.1158/1078-0432.ccr-06-0372.CrossRef

Gluck G, Hortopan M, Stanculeanu D, Chirita M, Stoica R, Sinescu I. Comparative study of conventional urothelial carcinoma, squamous differentiation carcinoma and pure squamous carcinoma in patients with invasive bladder tumors. J Med Life. 2014;7(2):211–4.PubMedPubMedCentral

Rausch S, Lotan Y, Youssef RF. Squamous cell carcinogenesis and squamous cell carcinoma of the urinary bladder: a contemporary review with focus on nonbilharzial squamous cell carcinoma. Urologic oncology. 2014;32(1):32.e11–6. doi:10.1016/j.urolonc.2012.11.020.

Wishahi M, Elganzoury H, Elhouly A, Badawi M. Urothelial carcinoma of the urinary bladder mixed with squamous differentiation or squamous cell carcinoma in areas with schistosomiasis is showing high risk of recurrence and poor survival. J Egypt Soc Parasitol. 2014;44(2):467–73.CrossRefPubMed

Raman JD, Jafri SM. Surgical management of bladder urothelial carcinoma with squamous differentiation. Urol Oncol. 2015;33(10):429–33. doi:10.1016/j.urolonc.2015.06.010.CrossRefPubMed

Antunes AA, Nesrallah LJ, Dall’Oglio MF, Maluf CE, Camara C, Leite KR, et al. The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy. Intern Braz J Urol : official journal of the Brazilian Society of Urology. 2007;33(3):339–45. discussion 46CrossRef

10.

Lopez-Beltran A, Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol. 2006;37(11):1371–88. doi:10.1016/j.humpath.2006.05.009.CrossRefPubMed

11.

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2016; doi:10.1016/j.eururo.2016.05.041.

12.

Jozwicki W, Domaniewski J, Skok Z, Wolski Z, Domanowska E, Jozwicka G. Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognosis: a mapping study. Urology. 2005;66(5):1122–6. doi:10.1016/j.urology.2005.06.134.CrossRefPubMed

13.

Billis A, Schenka AA, Ramos CC, Carneiro LT, Araujo V. Squamous and/or glandular differentiation in urothelial carcinoma: prevalence and significance in transurethral resections of the bladder. Int Urol Nephrol. 2001;33(4):631–3.CrossRefPubMed

14.

Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Modern Pathol : an official journal of the United States and Canadian Academy of Pathology, Inc. 2009;22(Suppl 2):S96–s118. doi:10.1038/modpathol.2009.26.CrossRef

15.

Erdemir F, Tunc M, Ozcan F, Parlaktas BS, Uluocak N, Kilicaslan I, et al. The effect of squamous and/or glandular differentiation on recurrence, progression and survival in urothelial carcinoma of bladder. Int Urol Nephrol. 2007;39(3):803–7. doi:10.1007/s11255-006-9151-0.CrossRefPubMed

16.

Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble a vitamin. J Exp Med. 1925;42(6):753–77.CrossRefPubMedPubMedCentral

17.

Gandhi D, Molotkov A, Batourina E, Schneider K, Dan H, Reiley M, et al. Retinoid signaling in progenitors controls specification and regeneration of the urothelium. Dev Cell. 2013;26(5):469–82. doi:10.1016/j.devcel.2013.07.017.CrossRefPubMedPubMedCentral

18.

Mauney JR, Ramachandran A, Yu RN, Daley GQ, Adam RM, Estrada CR. All-trans retinoic acid directs urothelial specification of murine embryonic stem cells via GATA4/6 signaling mechanisms. PLoS One. 2010;5(7):e11513. doi:10.1371/journal.pone.0011513.CrossRefPubMedPubMedCentral

19.

Liang FX, Bosland MC, Huang H, Romih R, Baptiste S, Deng FM, et al. Cellular basis of urothelial squamous metaplasia: roles of lineage heterogeneity and cell replacement. J Cell Biol. 2005;171(5):835–44. doi:10.1083/jcb.200505035.CrossRefPubMedPubMedCentral

20.

Molloy CJ, Laskin JD. Effect of retinoid deficiency on keratin expression in mouse bladder. Exp Mol Pathol. 1988;49(1):128–40.CrossRefPubMed

21.

Maraver A, Fernandez-Marcos PJ, Cash TP, Mendez-Pertuz M, Duenas M, Maietta P, et al. NOTCH pathway inactivation promotes bladder cancer progression. J Clin Invest. 2015;125(2):824–30. doi:10.1172/jci78185.CrossRefPubMedPubMedCentral

22.

Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, et al. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012;7(1):e30206. doi:10.1371/journal.pone.0030206.CrossRefPubMedPubMedCentral

23.

Guma S, Maglantay R, Lau R, Wieczorek R, Melamed J, Deng FM, et al. Papillary urothelial carcinoma with squamous differentiation in association with human papilloma virus: case report and literature review. Am J Clin Exp Urol. 2016;4(1):12–6.PubMedPubMedCentral

24.

Fujii T, Shimada K, Tatsumi Y, Hatakeyama K, Obayashi C, Fujimoto K et al. microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. BMC cancer. 2015;15:818. doi:10.1186/s12885-015-1846-0.

25.

Huang W, Williamson SR, Rao Q, Lopez-Beltran A, Montironi R, Eble JN, et al. Novel markers of squamous differentiation in the urinary bladder. Hum Pathol. 2013;44(10):1989–97. doi:10.1016/j.humpath.2013.04.005.CrossRefPubMed

26.

Tang Q, Xiong G, Li X, Fang D, Xi C, Zhang L, et al. The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy. World J Urol. 2016;34(6):871–7. doi:10.1007/s00345-015-1715-0.CrossRefPubMed

27.

Shapur NK, Katz R, Pode D, Shapiro A, Yutkin V, Pizov G, et al. Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors. 2011;3(2):e22. doi:10.4081/rt.2011.e22.CrossRefPubMedPubMedCentral

28.

Gofrit ON, Yutkin V, Shapiro A, Pizov G, Zorn KC, Hidas G, et al. The response of variant histology bladder cancer to Intravesical immunotherapy compared to conventional cancer. Front Oncol. 2016;6:43. doi:10.3389/fonc.2016.00043.CrossRefPubMedPubMedCentral

Title: Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival
Authors: Gang Li
Jianpeng Yu
Hualin Song
Shimiao Zhu
Libin Sun
Zhiqun Shang
Yuanjie Niu
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-017-3520-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients

Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol

Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging

Adjuvant chemotherapy versus chemoradiotherapy for small cell lung cancer with lymph node metastasis: a retrospective observational study with use of a national database in Japan

D-dimer levels and cerebral infarction in critically ill cancer patients

Detection of IKKε by immunohistochemistry in primary breast cancer: association with EGFR expression and absence of lymph node metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer